AstraZeneca heart drug in regulatory fast lane for wider use

LONDON, April 29 (Reuters) - U.S. regulators are to fast-track the review of a new use of AstraZeneca's heart drug Brilinta, meaning it could get the green light in the third quarter to be given to patients with a history of heart attacks.